Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.
Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.
The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.
Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.